The patient‐derived xenograft (PDX) model closely resembles the biological characteristics and genomic landscape of human cancers at the population level.[28, 29] To further confirm whether PUM1 could be used as a therapeutic target in GC, we assessed the antitumor activity of PUM1‐targeting siRNA in the PDX model. This evidence concerns the gene PUM1 and gastric cancer.